The recent surge in capital into specialized pharmaceutical companies, particularly those focusing on groundbreaking therapies and challenging drug development programs, has fueled what some are calling "High Investor Pharma." While the promise for revolutionary treatments and significant returns is undeniable, the connected risks are also consider